Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewProchlorperazine dimaleate
说明： D2 receptor antagonist; also 5-HT3 and nAChR antagonist
化学名： 2-Chloro-10-[3[(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine dimaleate
纯度： ≥98% (HPLC)
生物活性 for Prochlorperazine dimaleate
D2 receptor antagonist. Also interacts with 5-HT3 and nAChR. Displays antipsychotic, antispasmodic, antiemetic and antinociceptive activity in vivo.
化合物库 for Prochlorperazine dimaleate
Prochlorperazine dimaleate is also offered as part of the Tocriscreen FDA-Approved Drugs. 了解 Tocris 化合物库的更多信息。
技术数据 for Prochlorperazine dimaleate
| 分子量 | 606.09 |
| 公式 | C20H24ClN3S.2C4H4O4 |
| 储存 | Store at RT |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 84-02-6 |
| PubChem ID | 5281032 |
| InChI Key | DSKIOWHQLUWFLG-SPIKMXEPSA-N |
| Smiles | O=C(O)/C=C\C(O)=O.ClC4=CC2=C(C=C4)SC1=CC=CC=C1N2CCCN3CCN(C)CC3.O=C(O)/C=C\C(O)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for Prochlorperazine dimaleate
参考文献 for Prochlorperazine dimaleate
参考文献是支持产品生物活性的出版物。
Lummis and Baker (1997) Radioligand binding and photoaffinity labeling studies show a direct interaction of phenothiazenes at 5-HT3 receptors. Neuropharmacology 36 665 PMID: 9225292
Ghelardini et al (2004) Prochlorperazine induces central antinociception mediated by the muscarinic system. Pharmacol.Res. 50 351 PMID: 15225680
Satoh et al (2005) The antipsychotic and antiemetic drug prochlorper. delays the ventricular repolarization of the in situ canine heart. J.Pharm.Sci. 97 101
按标靶查看相关产品
按产品操作查看相关产品
关键词: Prochlorperazine dimaleate, Prochlorperazine dimaleate supplier, D2, receptor, antagonists, 5-HT3, nAChR, Dopamine, Receptors, serotonin, dopaminergic, Nicotinic, (Non-selective), 3287, Tocris Bioscience
1 篇 Prochlorperazine dimaleate 的引用文献
引用文献是使用了 Tocris 产品的出版物。 Prochlorperazine dimaleate 的部分引用包括：
Kenny et al (2015) Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Proc Natl Acad Sci U S A 6 6220 PMID: 25653139
Prochlorperazine dimaleate 的评论
目前没有该产品的评论。 Be the first to review Prochlorperazine dimaleate and earn rewards!
Have you used Prochlorperazine dimaleate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.